Skip Navigation
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC

Announcements

April 30, 2012

Health Awareness Topics - May 2012



NGC Spotlight


Visit the updated Hospital-Acquired Conditions page for evidence-based resources available on the NGC Web site to assist users in the prevention of the CMS-identified hospital-acquired conditions.

Conference News


The Guidelines International Network (G-I-N) Conference 2012, will be held August 22-25, 2012 in Berlin, Germany. Registration External Web Site Policy is now open.

U.S. Food and Drug Administration (FDA) Advisory


  • April 26, 2012: Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs External Web Site Policy: FDA notified healthcare professionals that the Victrelis drug label has been revised to state that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) protease inhibitor, along with certain ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors, is not recommended.
  • April 20, 2012: Aliskiren-containing Medications External Web Site Policy: FDA notified healthcare professionals of possible risks when using blood pressure medicines containing aliskiren with other drugs called angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with diabetes or kidney (renal) impairment. These drug combinations should not be used (are contraindicated) in patients with diabetes. In addition, avoid use of aliskiren with ARBs or ACEIs in patients with moderate to severe renal impairment. The labels for the aliskiren drugs are being updated based on preliminary data from a clinical trial

NGC's Sister Resources